CARA vs. JAN, PMN, OCUP, MRKR, UNCY, BCTX, XLO, BOLT, FBIO, and NXTC
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include JanOne (JAN), ProMIS Neurosciences (PMN), Ocuphire Pharma (OCUP), Marker Therapeutics (MRKR), Unicycive Therapeutics (UNCY), BriaCell Therapeutics (BCTX), Xilio Therapeutics (XLO), Bolt Biotherapeutics (BOLT), Fortress Biotech (FBIO), and NextCure (NXTC). These companies are all part of the "pharmaceutical preparations" industry.
JanOne (NASDAQ:JAN) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.
Cara Therapeutics received 664 more outperform votes than JanOne when rated by MarketBeat users.
JanOne has a beta of 2.34, suggesting that its stock price is 134% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500.
6.3% of JanOne shares are owned by institutional investors. Comparatively, 44.7% of Cara Therapeutics shares are owned by institutional investors. 3.0% of JanOne shares are owned by company insiders. Comparatively, 4.2% of Cara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
JanOne has a net margin of 0.00% compared to JanOne's net margin of -565.21%. JanOne's return on equity of -122.10% beat Cara Therapeutics' return on equity.
JanOne has higher revenue and earnings than Cara Therapeutics.
Cara Therapeutics has a consensus target price of $9.75, indicating a potential upside of 1,324.81%. Given JanOne's higher possible upside, analysts plainly believe Cara Therapeutics is more favorable than JanOne.
In the previous week, Cara Therapeutics had 1 more articles in the media than JanOne. MarketBeat recorded 3 mentions for Cara Therapeutics and 2 mentions for JanOne. Cara Therapeutics' average media sentiment score of 0.50 beat JanOne's score of 0.23 indicating that JanOne is being referred to more favorably in the media.
Summary
Cara Therapeutics beats JanOne on 8 of the 14 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
